France Bans Breast Implants Linked To Rare Cancer; Canada Close Behind
Executive Summary
There is now enough safety evidence to merit withdrawing macro-textured and polyurethane-coated breast implants from the market, according to health product regulators in France and Canada.
You may also be interested in...
The Evidence Is In: Australia Recommends Breast Implant Ban
The Therapeutic Goods Administration says it now has enough evidence to warrant cancelling, suspending and recalling a number of textured breast implants because of the potential risks of developing anaplastic large cell lymphoma.
Breast Implant-Makers Now Required To File Individual Reports On Each Adverse Event, FDA Says
The agency is redoubling efforts to warn women about the risks of silicone and saline breast implants after feedback from a recent advisory panel meeting. On 2 May, the regulator said it is requiring manufacturers to file individual Medical Device Reports for each adverse event regarding implants – part of a bigger effort to end its Alternative Summary Reporting Program for all devices.
'Do Your Job': To The Dismay Of Patients, FDA Panelists On Breast Implants Advise Better Risk Warnings, Not Recalls
Despite pleas from breast implant patients at a March 25-26 US FDA advisory committee meeting for the agency to take off the market silicone and saline breast implants that have initiated a serious range of symptoms in some women, the panel instead recommended FDA get out stronger public advisories warning of the risks of breast implants and a lymphoma associated with the products.